Protein Kinase Inhibitors: all 15,766 studies that test it

Page 158 of 158. Open to participants first (2,605), then studies with results posted, then the rest; newest registration first within each.

• Bryostatin 1 In Treating Patients With Progressive Kidney CancerCompletedNCT00005056Phase 2
• SU5416 in Treating Patients With AIDS-Related Kaposi's SarcomaCompletedNCT00005042Phase 2
• Paclitaxel and Bryostatin 1 in Treating Patients With Metastatic Prostate CancerCompletedNCT00005028Phase 2
• STI571 in Treating Patients With Recurrent LeukemiaCompletedNCT00004932Phase 1
• SU5416 in Treating Patients With Recurrent Astrocytoma or Mixed Glioma That Has Not Responded to Radiation TherapyCompletedNCT00004868Phase 1/2
• Phase III Randomized Study of Ursodiol With Vs Without Methotrexate for Primary Biliary CirrhosisCompletedNCT00004784Phase 3
• Study of Tauroursodeoxycholic Acid for Hepatobiliary Disease in Cystic FibrosisCompletedNCT00004441Not applicable
• Randomized Study of Tauroursodeoxycholic Acid in Prophylactic Therapy of Total Parenteral Nutrition Associated Cholestasis in InfantsCompletedNCT00004410Not applicable
• Phase II Pilot Study to Compare the Bioavailability of Buffered, Enteric-Coated Ursodiol With Unmodified Ursodiol for Chronic Cholestatic Liver Disease and Cystic Fibrosis-Associated Liver DiseaseStatus unknownNCT00004315Phase 2
• Cytarabine and UCN-01 in Treating Patients With Refractory or Relapsed Acute Myelogenous Leukemia or Myelodysplastic SyndromeCompletedNCT00004263Phase 1
• Letrozole or Tamoxifen in Treating Postmenopausal Women With Breast CancerCompletedNCT00004205Phase 3
• Bryostatin 1 Plus Gemcitabine in Treating Patients With Advanced CancerCompletedNCT00004144Phase 1
• Bryostatin 1 in Treating Patients With Ovarian Epithelial CancerCompletedNCT00004008Phase 2
• Bryostatin 1 and Interleukin-2 in Treating Patients With Refractory Solid Tumors or LymphomaCompletedNCT00003993Phase 1
• E7070 in Treating Patients With Solid TumorsCompletedNCT00003981Phase 1
• BIBX 1382 in Treating Patients With Solid TumorsSuspendedNCT00003980Phase 1
• E7070 in Treating Patients With Solid TumorsCompletedNCT00003976Phase 1
• Bryostatin 1 in Treating Patients With Metastatic Kidney CancerCompletedNCT00003968Phase 2
• Bryostatin 1 in Treating Patients With Recurrent or Refractory Hodgkin's DiseaseCompletedNCT00003936Phase 2
• SU5416 in Treating Patients With AIDS-Related Kaposi's SarcomaCompletedNCT00003720Phase 1
• CCI-779 in Treating Patients With Advanced Solid TumorsCompletedNCT00003712Phase 1
• Tamoxifen in Treating Women With Breast CancerStatus unknownNCT00003678Phase 3
• Flavopiridol in Treating Patients With Chronic Lymphocytic LeukemiaCompletedNCT00003620Phase 2
• Bryostatin 1 in Treating Patients With Metastatic or Recurrent Head and Neck CancerCompletedNCT00003443Phase 2
• Tamoxifen in Treating Patients With Primary Liver CancerCompletedNCT00003424Phase 3
• Exemestane Compared With Tamoxifen in Treating Postmenopausal Women With Primary Breast CancerStatus unknownNCT00003418Phase 3
• UCN-01 in Treating Patients With Advanced CancerCompletedNCT00003289Phase 1
• Flavopiridol in Treating Patients With Recurrent Prostate CancerCompletedNCT00003256Phase 2
• Bryostatin 1 Plus Paclitaxel and Cisplatin in Treating Patients With Advanced Solid TumorsCompletedNCT00003242Phase 1
• Bryostatin 1 in Treating Patients With Metastatic Colorectal CancerCompletedNCT00003220Phase 2
• Bryostatin 1 in Treating Patients With Stage IV Breast CancerCompletedNCT00003205Phase 2
• Bryostatin 1 Plus Cladribine in Treating Patients With Relapsed Chronic Lymphocytic LeukemiaCompletedNCT00003174Phase 1
• Bryostatin 1 in Treating Patients With Myelodysplastic SyndromeCompletedNCT00003171Phase 2
• Bryostatin and Vincristine in B-Cell MalignanciesCompletedNCT00003166Phase 1
• Bryostatin 1 Plus Cisplatin in Treating Patients With Metastatic or Unresectable CancerCompletedNCT00003132Phase 1
• Cisplatin Plus Bryostatin 1 in Treating Patients With Advanced CancerCompletedNCT00003108Phase 1
• Chemoprevention Therapy Plus Surgery in Treating Women With Breast CancerCompletedNCT00003099Phase 2
• Bryostatin 1 and High Dose Cytarabine in Treating Patients With Refractory or Relapsed Leukemia or LymphomaCompletedNCT00003079Phase 1
• Flavopiridol in Treating Patients With Recurrent Intermediate-Grade or High-Grade Non-Hodgkin's Lymphoma or Mantle Cell LymphomaCompletedNCT00003039Phase 2
• Prolonged Tamoxifen Compared With Shorter Tamoxifen in Treating Patients Who Have Breast CancerStatus unknownNCT00003016Phase 3
• Octreotide, Tamoxifen, and Chemotherapy in Treating Women With Breast CancerCompletedNCT00002967Phase 3
• Bryostatin 1 in Treating Patients With Relapsed Non-Hodgkin's Lymphoma or Chronic Lymphocytic LeukemiaCompletedNCT00002908Phase 2
• Bryostatin 1 in Treating Patients With Relapsed Multiple MyelomaCompletedNCT00002907Phase 2
• Tamoxifen With or Without Octreotide in Treating Postmenopausal Women With Stage I, Stage II, or Stage III Breast CancerCompletedNCT00002864Phase 3
• Prevention of Graft-Versus-Host Disease in Patients With Hematologic Malignancies Who Are Receiving a Bone Marrow TransplantWithdrawnNCT00002790Phase 1/2
• Exemestane Compared With Tamoxifen in Treating Women With Locally Recurrent or Metastatic Breast CancerCompletedNCT00002777Phase 3
• Bryostatin-1 in Treating Patients With Recurrent Non-Hodgkin's LymphomaCompletedNCT00002725Phase 2
• Surgery With or Without Lymph Node Removal in Treating Older Women With Stage I Breast CancerCompletedNCT00002720Phase 3
• Hormone Therapy in Treating Postmenopausal Women With Receptor-Positive Breast CancerCompletedNCT00002646Phase 3
• Tamoxifen for the Prevention of Breast Cancer in High-Risk WomenCompletedNCT00002644Phase 3
• Combination Chemotherapy and Tamoxifen in Treating Patients With Solid TumorsCompletedNCT00002608Phase 2
• Tamoxifen, Ovarian Ablation, and/or Chemotherapy in Treating Women With Stage I, Stage II, or Stage IIIA Breast CancerCompletedNCT00002582Phase 3
• Tamoxifen With or Without Combination Chemotherapy in Treating Postmenopausal Women With Operable Invasive Breast CancerCompletedNCT00002581Phase 3
• Tamoxifen, Ovarian Ablation, and/or Combination Chemotherapy in Treating Premenopausal Women With Stage I, Stage II, or Stage IIIA Invasive Breast CancerCompletedNCT00002580Phase 3
• Tamoxifen Following Combination Chemotherapy in Treating Women With Operable Invasive Breast CancerCompletedNCT00002579Phase 3
• Tamoxifen in Treating Women With High-Risk Breast CancerCompletedNCT00002542Phase 3
• Hormone Therapy and Chemotherapy in Treating Perimenopausal or Postmenopausal Women With Node-Positive Breast CancerCompletedNCT00002529Phase 3
• Stem Cell Transplantation Compared With Standard Chemotherapy in Treating Patients With Acute Lymphoblastic Leukemia in First RemissionCompletedNCT00002514Phase 3
• Adjuvant Hormone Therapy in Treating Women With Operable Breast CancerStatus unknownNCT00002460Phase 3
• The Safety and Effectiveness of Different Dose Levels of 1263W94 in the Treatment of Cytomegalovirus (CMV) of the Eyes in HIV-Infected PatientsCompletedNCT00002373Phase 1
• Safety and Effectiveness of Giving SU5416 to HIV-Infected Patients With AIDS-Related Kaposi's SarcomaCompletedNCT00002226Not applicable
• A Pharmacokinetic Study of Genistein, a Tyrosine Kinase InhibitorCompletedNCT00001696Phase 1
• A Phase I Trial of Continuous Infusion UCN-01 in Patients With Refractory NeoplasmsCompletedNCT00001444Phase 1
• A Phase I Study of OncoLAR® (Registered Trademark) (NSC 685403) With/Without Tamoxifen in Patients With OsteosarcomaCompletedNCT00001436Phase 1
• CVD Risk and Health in Postmenopausal Phytoestrogen UsersCompletedNCT00000613Phase 2
• Tamoxifen StudyCompletedNCT00000529Phase 3

← Protein Kinase Inhibitors overview